Related references
Note: Only part of the references are listed.Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group
Andrew L. Gilman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
Andrew D. J. Pearson et al.
LANCET ONCOLOGY (2008)
Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease
Thorsten Simon et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2006)
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
F Berthold et al.
LANCET ONCOLOGY (2005)
Infants with stage 4 neuroblastoma: The impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy
T Simon et al.
KLINISCHE PADIATRIE (2005)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
T Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age
F Berthold et al.
CANCER LETTERS (2003)
Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation:: A Children's Cancer Group Study
MF Ozkaynak et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
